Three Arrested In Japan For ¥320 Million Cancer Diagnostic Kit Fraud
This article was originally published in PharmAsia News
Tokyo police arrested three people for violating pharmaceutical affairs law and selling unapproved drugs without a permit. One suspect is the president of a Tokyo-based medical service company and another is president of a Kobe-based importer. The suspects claimed the diagnostic kit, imported from Hong Kong, can tell whether a person has cancer by using urine samples. By the time of arrest, they had sold 180,000 kits and made profit of ¥320 million. According to the authorities, the kit is made of mercury and nickel and has no proven effects. (Click here for more - Japanese language) "Three Arrested For Cancer Test Kit Fraud" - Sankei News (7/18/08)
You may also be interested in...
One effect of Brexit is that the UK’s National Institute for Biological Standards and Control will have additional responsibilities from next year in terms of the independent batch testing and release of products such as vaccines and medicines derived from human blood and plasma in Great Britain.
Sun Pharma and its US Taro subsidiary have further criticized a recent CMS policy proposal that would see Medicare Part B drugs approved under the US hybrid 505(b)(2) pathway reimbursed at a lower rate applicable to multiple source products.
An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.